Aquestive Therapeutics annual debt-to-assets ratio
2019
2020
2021
2022
2023
2024
2025
Aquestive Therapeutics Debt-to-Assets Ratio Growth & History (AQST)
Aquestive Therapeutics's debt-to-assets ratio was 0.20 for fiscal 2025.
View full Aquestive Therapeutics company overviewAquestive Therapeutics annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.20 | −0.17 | −45.92% |
| 2024 | 2024-12-31 | 0.37 | 0.01 | +3.65% |
| 2023 | 2023-12-31 | 0.36 | −0.32 | −46.85% |
| 2022 | 2022-12-31 | 0.68 | 0.63 | +1380.98% |
| 2021 | 2021-12-31 | 0.05 | −0.83 | −94.76% |
| 2020 | 2020-12-31 | 0.88 | −0.02 | −1.81% |
| 2019 | 2019-12-31 | 0.89 | — | — |
Aquestive Therapeutics quarterly debt-to-assets ratio
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.45 | −0.09 | −16.70% |
| Q1 2026 | 2026-03-31 | 0.21 | −0.28 | −56.96% |
| Q4 2025 | 2025-12-31 | 0.20 | −0.17 | −45.92% |
| Q3 2025 | 2025-09-30 | 0.31 | 0.08 | +37.92% |
| Q2 2025 | 2025-06-30 | 0.54 | 0.34 | +172.15% |
| Q1 2025 | 2025-03-31 | 0.49 | 0.32 | +192.46% |
| Q4 2024 | 2024-12-31 | 0.37 | 0.01 | +3.65% |
| Q3 2024 | 2024-09-30 | 0.22 | −0.53 | −70.56% |
| Q2 2024 | 2024-06-30 | 0.20 | −0.59 | −75.01% |
| Q1 2024 | 2024-03-31 | 0.17 | −0.62 | −78.69% |
| Q4 2023 | 2023-12-31 | 0.36 | −0.32 | −46.85% |
| Q3 2023 | 2023-09-30 | 0.75 | −0.28 | −27.14% |
| Q2 2023 | 2023-06-30 | 0.79 | −0.17 | −17.66% |
| Q1 2023 | 2023-03-31 | 0.79 | −0.17 | −17.45% |
| Q4 2022 | 2022-12-31 | 0.68 | 0.63 | +1380.98% |
| Q3 2022 | 2022-09-30 | 1.04 | 0.20 | +23.96% |
| Q2 2022 | 2022-06-30 | 0.96 | 0.14 | +16.98% |
| Q1 2022 | 2022-03-31 | 0.96 | 0.07 | +7.97% |
| Q4 2021 | 2021-12-31 | 0.05 | −0.83 | −94.76% |
| Q3 2021 | 2021-09-30 | 0.84 | −0.63 | −42.85% |
| Q2 2021 | 2021-06-30 | 0.82 | −0.34 | −29.64% |
| Q1 2021 | 2021-03-31 | 0.89 | −0.26 | −22.74% |
| Q4 2020 | 2020-12-31 | 0.88 | −0.02 | −1.81% |
| Q3 2020 | 2020-09-30 | 1.46 | 0.03 | +1.95% |
| Q2 2020 | 2020-06-30 | 1.16 | — | — |
| Q1 2020 | 2020-03-31 | 1.15 | — | — |
| Q4 2019 | 2019-12-31 | 0.89 | — | — |
| Q3 2019 | 2019-09-30 | 1.43 | — | — |
Aquestive Therapeutics debt-to-assets ratio trends
Over the last five fiscal years, Aquestive Therapeutics's debt-to-assets ratio decreased from 0.88 to 0.20, a change of −0.67. The latest reported quarter, Q2 2026, shows 0.45.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aquestive Therapeutics source filings ↗